Payment overview · 2025
General Payments
$330.93
9 reported records · 6 companies
Healthcare provider profile · identity verified
Tushar R. Modi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MODESTO, CA · NPI 1679551352
Verified facts
What the public records show
CMS Open Payments records show Tushar R. Modi, M.D. received $330.93 in general payments during 2025 across 9 reported records.
Astellas Pharma US Inc accounted for 51.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $169.98 | 51.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $83.65 | 25.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 13.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.62 | 4.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.84 | 4.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3.84 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $214.98 | 3 |
| Food and Beverage | $66.00 | 5 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $3.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
303 | 89 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
255 | 63 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
54 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1722 | 446 |
| Amlodipine Besylate | Amlodipine Besylate | 1383 | 385 |
| Losartan Potassium | Losartan Potassium | 1241 | 343 |
| Metoprolol Succinate | Metoprolol Succinate | 1142 | 313 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1099 | 283 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 851 | 254 |
| Pantoprazole Sodium | Pantoprazole Sodium | 694 | 202 |
| Metformin Hcl | Metformin Hcl | 584 | 187 |
| Furosemide | Furosemide | 570 | 160 |
| Tamsulosin Hcl | Tamsulosin Hcl | 551 | 159 |
| Telmisartan | Telmisartan | 421 | 123 |
| Metoprolol Tartrate | Metoprolol Tartrate | 380 | 115 |
| Azithromycin | Azithromycin | 379 | 268 |
| Hydralazine Hcl | Hydralazine Hcl | 371 | 110 |
| Gabapentin | Gabapentin | 360 | 114 |
| Carvedilol | Carvedilol | 353 | 95 |
| Sertraline Hcl | Sertraline Hcl | 343 | 96 |
| Finasteride | Finasteride | 341 | 96 |
| Jardiance | Empagliflozin | 303 | 89 |
| Spironolactone | Spironolactone | 276 | 83 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 263 | 179 |
| Glipizide Er | Glipizide | 259 | 78 |
| Eliquis | Apixaban | 255 | 63 |
| Lisinopril | Lisinopril | 255 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 251 | 33 |
| Omeprazole | Omeprazole | 247 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 235 | 62 |
| Ezetimibe | Ezetimibe | 218 | 60 |
| Montelukast Sodium | Montelukast Sodium | 204 | 53 |
| Alprazolam | Alprazolam | 200 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 200 | 74 |
| Donepezil Hcl | Donepezil Hcl | 188 | 41 |
| Lorazepam | Lorazepam | 187 | 54 |
| Valsartan | Valsartan | 184 | 50 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 179 | 124 |
| Memantine Hcl | Memantine Hcl | 177 | 46 |
| Potassium Chloride | Potassium Chloride | 177 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 45 |
| Famotidine | Famotidine | 165 | 28 |
| Allopurinol | Allopurinol | 162 | 44 |
| Trazodone Hcl | Trazodone Hcl | 148 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 138 | 35 |
| Levofloxacin | Levofloxacin | 121 | 87 |
| Xarelto | Rivaroxaban | 121 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 50 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 115 | 45 |
| Prednisone | Prednisone | 111 | 67 |
| Estradiol | Estradiol | 108 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 26 |
| Amoxicillin | Amoxicillin | 102 | 79 |
| Benazepril Hcl | Benazepril Hcl | 101 | 33 |
| Nateglinide | Nateglinide | 100 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 28 |
| Tramadol Hcl | Tramadol Hcl | 95 | 28 |
| Alendronate Sodium | Alendronate Sodium | 92 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 23 |
| Azelastine Hcl | Azelastine Hcl | 90 | 35 |
| Clonazepam | Clonazepam | 89 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 86 | 25 |
| Irbesartan | Irbesartan | 85 | 23 |
| Cephalexin | Cephalexin | 84 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 20 |
| Simvastatin | Simvastatin | 83 | 23 |
| Divalproex Sodium | Divalproex Sodium | 82 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 81 | 27 |
| Januvia | Sitagliptin Phosphate | 80 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 31 |
| Myrbetriq | Mirabegron | 76 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 72 | 21 |
| Synthroid | Levothyroxine Sodium | 71 | 19 |
| Benzonatate | Benzonatate | 69 | 39 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 69 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 22 |
| Trospium Chloride | Trospium Chloride | 67 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 37 |
| Dutasteride | Dutasteride | 62 | 21 |
| Ketoconazole | Ketoconazole | 62 | 42 |
| Linzess | Linaclotide | 60 | 16 |
| Olanzapine | Olanzapine | 58 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 57 | 19 |
| Risperidone | Risperidone | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 16 |
| Aripiprazole | Aripiprazole | 54 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 54 | 52 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Folic Acid | Folic Acid | 52 | 15 |
| Metronidazole | Metronidazole | 52 | 31 |
| Levetiracetam | Levetiracetam | 51 | 13 |
| Glipizide | Glipizide | 47 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 13 |
| Acyclovir | Acyclovir | 46 | 18 |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 40 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | 11 |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | 13 |
| Mupirocin | Mupirocin | 38 | 27 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 37 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 37 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 13 |
| Calcitriol | Calcitriol | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Ramipril | Ramipril | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Nystatin | Nystatin | 34 | 19 |
| Topiramate | Topiramate | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Digoxin | Digoxin | 32 | 12 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 32 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 32 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | 11 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 28 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 16 |
| Sucralfate | Sucralfate | 27 | 15 |
| Metolazone | Metolazone | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | 12 |
| Ozempic | Semaglutide | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 25 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 11 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 12 |
| Nitroglycerin | Nitroglycerin | 22 | 15 |
| Valacyclovir | Valacyclovir Hcl | 22 | 18 |
| Constulose | Lactulose | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | 12 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | 15 |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Dupixent Pen | Dupilumab | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluorouracil | Fluorouracil | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $330.93 · 9 records | Astellas Pharma US Inc | ABRYSVO, COMIRNATY, FREESTYLE INSULINX, FREESTYLE LIBRE 3, PREVNAR 20, TRELEGY ELLIPTA, VOQUEZNA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error